Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$653.09+4.89 (+0.75%)
Close on Nov 17, 2026Market cap $18.27BP/E 36.2Yield –
Medpace total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Medpace's total debt was $0 at Dec 31, 2023. For fiscal 2023 it was $0, down 100.0% from the year before. The highest annual figure on record is $377.94M in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $50.00M | – |
| FY2021 | Dec 31, 2021 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $79.72M | -64.0% |
| FY2017 | Dec 31, 2017 | $221.61M | +35.4% |
| FY2016 | Dec 31, 2016 | $163.64M | -56.7% |
| FY2015 | Dec 31, 2015 | $377.94M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $55.00M | -78.0% |
| Q1 FY2023 | Mar 31, 2023 | $115.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $50.00M | – |
| Q3 FY2022 | Sep 30, 2022 | $139.70M | – |
| Q2 FY2022 | Jun 30, 2022 | $249.70M | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $55.78M | -71.8% |
| Q4 FY2018 | Dec 31, 2018 | $79.72M | -64.0% |
| Q3 FY2018 | Sep 30, 2018 | $113.69M | -38.4% |
| Q2 FY2018 | Jun 30, 2018 | $163.52M | +3.7% |
| Q1 FY2018 | Mar 31, 2018 | $197.57M | +23.0% |
| Q4 FY2017 | Dec 31, 2017 | $221.61M | +35.4% |
| Q3 FY2017 | Sep 30, 2017 | $184.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $157.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $160.64M | – |
| Q4 FY2016 | Dec 31, 2016 | $163.64M | – |
See a number that looks wrong?